---
title: "AVICHINA: AVICOPTER's annual net profit attributable to the parent company is 556 million yuan, a year-on-year decrease of 7.98%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/233646227.md"
description: "According to the Zhitong Finance APP, AVICHINA released the annual report for its subsidiary AVICOPTER for 2024, with operating revenue of 29.766 billion yuan (RMB, the same below), an increase of 11.93% year-on-year; net profit attributable to the parent company of 556 million yuan, a decrease of 7.98% year-on-year; basic earnings per share of 0.7234 yuan"
datetime: "2025-03-28T13:42:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/233646227.md)
  - [en](https://longbridge.com/en/news/233646227.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/233646227.md)
generator: "portal-rs"
---

# AVICHINA: AVICOPTER's annual net profit attributable to the parent company is 556 million yuan, a year-on-year decrease of 7.98%

According to the Zhitong Finance APP, AVICHINA (02357) released the annual report for its subsidiary AVICOPTER (600038.SH) for 2024, with operating revenue of 29.766 billion yuan (RMB, the same below), an increase of 11.93% year-on-year; net profit attributable to the parent company of 556 million yuan, a decrease of 7.98% year-on-year; basic earnings per share of 0.7234 yuan

### Related Stocks

- [02357.HK](https://longbridge.com/en/quote/02357.HK.md)
- [600038.CN](https://longbridge.com/en/quote/600038.CN.md)

## Related News & Research

- [Hyundai Mobis Accelerates Electrification Push in Europe with Opening of New Plant in Slovakia](https://longbridge.com/en/news/297851408.md)
- [Frogbet Launches Crypto Casino With 70 In- House Original Games, Instant Withdrawals and a $10,000 Weekly Race](https://longbridge.com/en/news/297616927.md)
- [KUAISHOU-W Buys back 455,000 Shares for ~HKD15M](https://longbridge.com/en/news/297979199.md)
- [09:06 ETRELATABLE TEAMS UP WITH THE NFL TO BRING EMOTIONAL SUPPORT TO FOOTBALL FANS](https://longbridge.com/en/news/297919611.md)
- [Keymed Biosciences licenses Stapokibart marketing, sales rights in 18 Southeast and Central Asia markets to Aeira](https://longbridge.com/en/news/297791065.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**